NGeneBio joins US gov't Cancer Moonshot project

It plans to collaborate with global companies to build next-generation sequencing precision diagnosis platforms

NGeneBio joins US gov't Cancer Moonshot project
Jeong Min Nam 1
2023-10-10 17:21:02 peux@hankyung.com
Bio & Pharma

South Korean medical diagnostic company NGeneBio Co. announced on Tuesday it joins US President Joe Biden's cancer-conquering project "Cancer Moonshot."

The Cancer Moonshot is a policy by the Biden Administration aiming to reduce the cancer mortality rate by over 50% in the next 25 years. An annual investment of $1.8 billion is dedicated to introducing cancer treatments and diagnostic technologies.

"Through participation in Cancer Moonshot, we will establish various collaborative systems related to the next-generation sequencing (NGS) precision diagnosis platform with leading global companies," an NGeneBio source said. 

NGeneBio is a company that has commercialized the NGeneAnalySys cancer precision diagnosis platform, which includes solid tumor and hematologic cancer gene diagnostic panels and data analysis software. It is currently being used for personalized cancer treatment in more than 20 medical institutions in South Korea and in countries like Germany and Singapore.

With its participation in Cancer Moonshot, NGeneBio plans to commercialize software packages that integrate NGS analysis results with hospital electronic medical record (EMR) systems through its US subsidiary NGeneBioAI. Additionally, it will collaborate with other companies participating in Cancer Moonshot on the development of genetic machine learning research models.

"Through this opportunity, we expect revenue growth in the US market, with expanded companion diagnostics and the advancement of AI technology for genomic analysis," said NGeneBio CEO Choi Dae-Chul.

Write to Jeong Min Nam at peux@hankyung.com
#NGeneBio #Cancer Moonshot #CancerX #next-generation sequencing #EMR #NGeneBioAI

NGeneBio applies for US patent of early diagnosis tech of dementia

NGeneBio applies for US patent of early diagnosis tech of dementia

South Korean medical diagnostic company NGeneBio Co. announced on Thursday that it has completed the US patent application for its technology related to the diagnosis and monitoring of degenerative brain diseases based on body fluid-based tests.The technology applied for the patent this time a

S.Korea's NGeneBio establishes US corporation NGeneBioAI

S.Korea's NGeneBio establishes US corporation NGeneBioAI

South Korean medical diagnostic company NGeneBio Co. announced on Monday that it has established an artificial intelligence (AI) precision diagnostic firm called "NGeneBioAI" in the US. NGeneBioAI has been fully funded by its parent company, NGeneBio. It is expected to play a pivotal role

NGeneBio to launch precision cancer test service in Thailand

NGeneBio to launch precision cancer test service in Thailand

South Korean medical diagnostic company NGeneBio Co. has partnered with MP Group, a large consignment testing agency in Thailand, to launch a precision cancer test service based on next-generation sequencing (NGS).On Jan. 30, NGenBio presented the need for NGS precision diagnosis and introduce

NGeneBio's diagnostic products start to be used in clinical tests in Vietnam

NGeneBio's diagnostic products start to be used in clinical tests in Vietnam

NGeneBio's researchers (Hankyung DB) South Korea's medical diagnostics company NGeneBio Co. said on Wednesday that it is expanding its business in the Southeast Asian precision diagnostics market.The Kosdaq-listed firm is a next-generation sequencing (NGS) precision diagnosis platform company.

LabGenomics, NGeneBio join forces for US market

LabGenomics, NGeneBio join forces for US market

NGeneBio and LabGenomics signed an MOU to move into the US market (Yonhap) Korea's two diagnostics companies, NGeneBio Co. and LabGenomics Co., signed a memorandum of understanding (MOU) on Thursday to cooperate in the field of next-generation sequencing (NGS) services.The two companies will wo
(* comment hide *}